MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
about
MicroRNAs: novel players in cancer diagnosis and therapies.Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo.MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.MicroRNA-mediated drug resistance in ovarian cancer.MicroRNA 17-5p regulates autophagy in Mycobacterium tuberculosis-infected macrophages by targeting Mcl-1 and STAT3.miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.The emergence of noncoding RNAs as Heracles in autophagy.Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1.miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1α.miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes.The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy.The Network of Non-coding RNAs in Cancer Drug Resistance
P2860
Q33914573-0B8A5892-4119-4089-9A40-05044D06A659Q34406244-6D30A63F-6698-43A1-A0DF-4DCA8061D7D0Q36299580-1CC7008B-5999-42BD-90B1-2118C169C6D2Q38258014-61B42FC2-06F3-4743-AE35-45D784C619B3Q38366731-A224BA95-B739-4F98-84A9-67B9D857A232Q38544386-401274F3-B8A5-4757-8FAF-3EBD1ED899B8Q38546133-819F5CB6-C38C-4D13-9B84-3AA029858256Q38633144-EB65EAA0-0629-4396-BCE0-B48BA3E3DAEAQ39382756-5D9E5A81-A3FA-497C-B641-B155855DE0EDQ40932500-F3F88FBD-D8C2-4AD1-8C6D-CA4368F220C1Q42735024-71DB7E3A-38B7-4223-B5D7-38FD5D078CC4Q46377062-8443D085-2ACD-42AB-A7E3-6526B6609918Q47114053-3617EB23-93D3-4585-A578-53E4E75594BFQ47127678-E905E785-4EF9-4C0C-ACFE-869458CD56B1Q47367402-C2B3196D-6444-481D-A296-D21BDA3BA922Q53220492-0530DA07-72EE-446B-B396-0BD71AEFB168Q55399368-8EEFCA24-4305-4CD1-9671-E466F32EEF29Q58694197-B53908FE-A582-433D-BBA3-DA90ACF72A2A
P2860
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@en
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@nl
type
label
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@en
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@nl
prefLabel
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@en
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@nl
P2093
P2860
P1476
MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
@en
P2093
Cai-hong Chen
Hui-rong Shi
Yu-mei Rao
P2860
P2888
P304
P356
10.1007/S11596-013-1160-5
P577
2013-08-01T00:00:00Z